Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Visual Impairment
Conditions
Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macula Edema (DME)
Trial Timeline
Feb 15, 2024 → Jan 31, 2028
NCT ID
NCT06075147About Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) is a pre-clinical stage product being developed by Bayer for Visual Impairment. The current trial status is active. This product is registered under clinical trial identifier NCT06075147. Target conditions include Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macula Edema (DME).
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06075147 | Pre-clinical | Active |
Competing Products
13 competing products in Visual Impairment
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 77 |
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 77 |
| Blink® Tears eye drops + Investigational lipid eye drops | Johnson & Johnson | Phase 1 | 33 |
| Blink® Tears eye drops in a multidose bottle + Preservative-free investigational lubricating eye drops in a Novelia® eyedropper | Johnson & Johnson | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab + Aflibercept | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |
| Sham injections + Ranibizumab 0.5 mg | Novartis | Phase 3 | 77 |
| Ranibizumab + Dexamethasone implant and sham injections | Novartis | Phase 3 | 77 |
| Ranibizumab + Aflibercept | Novartis | Approved | 85 |
| Intravitreal Lucentis 0.5mg | Novartis | Pre-clinical | 23 |
| ZK200775 + ZK200775 + Sodium Chloride | Bayer | Phase 1 | 30 |